DK3860598T3 - Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner - Google Patents
Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner Download PDFInfo
- Publication number
- DK3860598T3 DK3860598T3 DK19790573.0T DK19790573T DK3860598T3 DK 3860598 T3 DK3860598 T3 DK 3860598T3 DK 19790573 T DK19790573 T DK 19790573T DK 3860598 T3 DK3860598 T3 DK 3860598T3
- Authority
- DK
- Denmark
- Prior art keywords
- vemurafenib
- salts
- treatment
- enterovirus infections
- enterovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20185830 | 2018-10-03 | ||
| PCT/FI2019/050712 WO2020070390A1 (en) | 2018-10-03 | 2019-10-03 | Vemurafenib and salts thereof for use in the treatment of enteroviral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3860598T3 true DK3860598T3 (da) | 2023-10-16 |
Family
ID=68296508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19790573.0T DK3860598T3 (da) | 2018-10-03 | 2019-10-03 | Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210244716A1 (da) |
| EP (1) | EP3860598B1 (da) |
| DK (1) | DK3860598T3 (da) |
| FI (1) | FI3860598T3 (da) |
| WO (1) | WO2020070390A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4153174A1 (en) * | 2020-05-19 | 2023-03-29 | Board of Regents, The University of Texas System | Methods for the treatment of pancreatitis and prevention of pancreatic cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994018960A1 (en) | 1993-02-26 | 1994-09-01 | Schering Corporation | Use of 2-chloro-1-[[4-[(2,6-dichlorophenoxy)methyl]-phenyl]methoxy]-4-methoxy-benzene for the selective treatment of enteroviral infections in humans |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2585067B1 (en) | 2010-06-25 | 2017-08-09 | Biota Scientific Management Pty Ltd | Compound for the treatment of enteroviruses |
| EA201590041A1 (ru) | 2012-07-03 | 2015-04-30 | Ратиофарм Гмбх | Твердая форма холиновой соли вемурафениба |
| JP6294889B2 (ja) | 2012-10-08 | 2018-03-14 | アトリバ セラピューティクス ゲーエムベーハー | ウイルス疾患の処置におけるｍｅｋ阻害物質 |
| JP2016512518A (ja) * | 2013-03-14 | 2016-04-28 | ラシオファルム ゲーエムベーハー | ベムラフェニブ塩酸塩の固体形態 |
| WO2016073421A1 (en) * | 2014-11-03 | 2016-05-12 | Dispersol Technologies, Llc | Improved formulations of vemurafenib and methods of making the same |
| EP3223817A4 (en) | 2014-11-29 | 2018-05-30 | Shilpa Medicare Limited | Substantially pure vemurafenib and its salts |
| CZ2015257A3 (cs) | 2015-04-16 | 2016-10-26 | Zentiva, K.S. | Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu |
| EP3419980A4 (en) | 2016-02-26 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY |
| WO2018002415A1 (en) | 2016-07-01 | 2018-01-04 | Fermion Oy | New processes for the preparation of vemurafenib |
-
2019
- 2019-10-03 DK DK19790573.0T patent/DK3860598T3/da active
- 2019-10-03 WO PCT/FI2019/050712 patent/WO2020070390A1/en unknown
- 2019-10-03 US US17/281,650 patent/US20210244716A1/en active Pending
- 2019-10-03 FI FIEP19790573.0T patent/FI3860598T3/fi active
- 2019-10-03 EP EP19790573.0A patent/EP3860598B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020070390A1 (en) | 2020-04-09 |
| FI3860598T3 (fi) | 2023-10-26 |
| EP3860598A1 (en) | 2021-08-11 |
| EP3860598B1 (en) | 2023-09-06 |
| US20210244716A1 (en) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
| DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
| DK3612517T3 (da) | Bicykliske forbindelser og deres anvendelse ved behandling af cancer | |
| DK3313401T3 (da) | Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer | |
| DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
| DK3215511T3 (da) | Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser | |
| DK3322425T3 (da) | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi | |
| DK3704108T3 (da) | Irak4-hæmmer i kombination med en bcl-2-hæmmer til anvendelse i cancerbehandling | |
| DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
| DK3377637T3 (da) | Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden | |
| DK3641819T3 (da) | Anvendelse af cannabidiol i behandling af tuberøst sklerosekompleks | |
| DK3464368T3 (da) | Anvendelse af et anti-pd-1-antistof i kombination med et anti-cd30- antistof i lymfombehandling | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| DK3902803T3 (da) | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3160234T3 (da) | Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst | |
| DK3860990T3 (da) | Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer | |
| DK3570940T3 (da) | Pridopidin til anvendelse i behandling af fragilt x-syndrom | |
| DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
| DK3962601T3 (da) | 5-HT2A-agonister til anvendelse til behandling af depression | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer |